<?xml version="1.0" encoding="UTF-8"?>
<p id="par0225">Ribavirin is an approved drug developed to treat HCV and especially children hospitalized for the treatment of the respiratory syncytial virus (RSV). According to Kim et al. [
 <xref rid="bib0565" ref-type="bibr">113</xref>] 
 <italic>in vivo</italic> studies performed with combinations of lopinavir/ribavirin (LPV/r), Ribavirin and interferon resulted in the cure of a 64-year-old MERS patient from Korea after 6 days of treatment. In addition, the combination of LPV/r and interferon was also included in a study for a randomized control in Saudi Arabia to MERS patients [
 <xref rid="bib0570" ref-type="bibr">114</xref>].
</p>
